LivaNova (NASDAQ:LIVN) Shares Gap Up - Should You Buy?

Shares of LivaNova PLC (NASDAQ:LIVN - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $52.97, but opened at $55.23. LivaNova shares last traded at $55.74, with a volume of 145,438 shares trading hands.

Analysts Set New Price Targets

A number of analysts have weighed in on LIVN shares. Baird R W raised shares of LivaNova from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 17th. Stifel Nicolaus upped their target price on shares of LivaNova from $70.00 to $72.00 and gave the stock a "buy" rating in a report on Thursday, July 25th. Needham & Company LLC upped their target price on shares of LivaNova from $72.00 to $75.00 and gave the stock a "buy" rating in a research note on Wednesday, July 31st. Robert W. Baird raised LivaNova from a "neutral" rating to an "outperform" rating and increased their price target for the company from $55.00 to $66.00 in a research report on Tuesday, September 17th. Finally, The Goldman Sachs Group assumed coverage on shares of LivaNova in a research note on Friday, October 4th. They issued a "buy" rating and a $65.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, LivaNova presently has a consensus rating of "Buy" and a consensus target price of $69.83.

LivaNova Trading Down 3.1 %

The company has a market cap of $2.78 billion, a P/E ratio of -88.28 and a beta of 1.00. The stock has a 50-day moving average of $50.83 and a two-hundred day moving average of $53.16. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.94 and a current ratio of 3.45.

LivaNova (NASDAQ:LIVN - Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.66 by $0.15. LivaNova had a positive return on equity of 13.77% and a negative net margin of 1.37%. The firm had revenue of $318.60 million for the quarter, compared to the consensus estimate of $305.05 million. On average, equities research analysts predict that LivaNova PLC will post 2.58 earnings per share for the current year.

Hedge Funds Weigh In On LivaNova

Several hedge funds have recently modified their holdings of LIVN. Hexagon Capital Partners LLC increased its stake in LivaNova by 117.8% in the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company's stock worth $37,000 after buying an additional 370 shares during the period. Fifth Third Bancorp boosted its holdings in LivaNova by 97.1% in the second quarter. Fifth Third Bancorp now owns 674 shares of the company's stock valued at $37,000 after purchasing an additional 332 shares during the last quarter. Lazard Asset Management LLC purchased a new position in shares of LivaNova during the 1st quarter valued at approximately $84,000. Canada Pension Plan Investment Board acquired a new position in LivaNova in the 2nd quarter worth about $88,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of LivaNova during the first quarter worth about $94,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.